Comparative analysis of the efficacy of Opicapone and other COMT inhibitors

Opicapone (trade name: Ongentys) is a new oral Catechol-O-methyltransferase (COMT) inhibitor is used to assist levodopa in the treatment of "on-off" fluctuation symptoms in patients with Parkinson's disease (PD). By inhibiting peripheral COMT, Opicapone prolongs the half-life of levodopa in the blood and increases the availability of dopamine in the central nervous system, thereby improving motor function and reducing "off" time. Compared with traditional COMT inhibitors (such as entacapone and tolcapone), opicapone has the advantage of long half-life and once-daily administration.

Clinical studies have shown that opicapone combined with levodopa can significantly reduce the daily "off" time and increase the "on" time without increasing drowsiness. Compared with entacapone, opicapone has equivalent or even slightly better efficacy when taken once daily, while reducing blood concentration fluctuations caused by multiple doses. Although tolcapone can inhibit COMT, it requires multiple doses per day and has many side effects, such as diarrhea and abnormal liver function. Opicapone reduces this inconvenience by relying on its long-term effect.

Opicapone was generally well tolerated, with common side effects including mild constipation, insomnia, or blood pressure fluctuations. Compared with entacapone, opicapone has a lower incidence of liver function abnormalities and gastrointestinal adverse events; compared with tolcapone, because it only needs to be administered once a day, patient compliance is higher and the risk of long-term use is relatively small. Clinical practice shows that Opicapone improves patients' quality of life and treatment compliance while ensuring efficacy.

Taken together, opicapone has the advantages of convenience, stable efficacy, and low side effects compared with traditional COMT inhibitors in the adjuvant treatment of Parkinson's disease. It is especially suitable for patients who experience "on-off" fluctuations during long-term levodopa treatment, and can be used as an alternative to entacapone or tolcapone. At the same time, for patients with poor compliance or who wish to reduce the number of daily medication doses, Opicapone provides a more convenient, safe and effective option. Clinicians can take opicapone into consideration when formulating comprehensive treatment plans for Parkinson's disease to optimize motor control and improve quality of life.

Reference link:https://www.drugs.com